Cannabidiol efficacy in treating panic disorder
Pro Research Analysisby 
Searched over 200M research papers
Cannabidiol (CBD) and Panic Disorder: Current Research Overview
CBD Efficacy in Anxiety and Panic Disorders
Research on cannabidiol (CBD) has shown promising results for several anxiety-related disorders, including generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder, with both preclinical and clinical studies supporting its anxiolytic effects 1235+4 MORE. However, when it comes specifically to panic disorder, the evidence is much more limited.
Preclinical and Clinical Evidence for Panic Disorder
Preclinical studies using animal models have found that CBD can produce panicolytic-like effects, suggesting potential benefits for panic disorder 2378. These studies indicate that CBD may help reduce panic-like behaviors and stress responses, likely through its action on the endocannabinoid system and CB1 receptors 2378.
In human studies, there is a lack of direct evidence evaluating CBD as a treatment for panic disorder. Most clinical trials have focused on other anxiety disorders, and systematic reviews have noted the absence of studies specifically targeting panic disorder 15. One randomized controlled trial included patients with panic disorder with agoraphobia and tested CBD as an adjunct to exposure therapy. The results showed no significant difference in treatment outcomes between the CBD and placebo groups, indicating that CBD did not enhance the effects of exposure therapy for panic disorder in this setting .
Safety and Tolerability of CBD
Across studies, CBD has generally been well-tolerated, with mild side effects such as fatigue and sedation being the most commonly reported 13910. No serious or unexpected adverse events have been observed in clinical trials, even at higher doses 910.
Limitations and Need for Further Research
While preclinical evidence supports the potential of CBD for panic disorder, clinical research is still lacking. Most human studies have not included panic disorder as a primary focus, and the few that have, such as the trial on panic disorder with agoraphobia, did not find significant benefits 145. Additionally, there is a need for more research on chronic dosing, long-term effects, and the impact of CBD in diverse populations, including females and young people 310.
Conclusion
CBD shows promise as an anxiolytic agent in preclinical models of panic disorder, but current clinical evidence is insufficient to support its efficacy for treating panic disorder in humans. More targeted clinical trials are needed to determine whether CBD can be an effective treatment for panic disorder specifically, as well as to establish optimal dosing and long-term safety. For now, CBD remains a potential but unproven option for panic disorder, with stronger evidence supporting its use in other anxiety-related conditions 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Use of cannabidiol in anxiety and anxiety-related disorders.
CBD shows promise as an alternative therapy for anxiety disorders, with promising results in generalized anxiety disorder, social anxiety disorder, and posttraumatic stress syndrome.
Cannabidiol as a Potential Treatment for Anxiety Disorders
CBD shows considerable potential as a treatment for multiple anxiety disorders when administered acutely, but further study is needed on chronic effects and therapeutic effects in clinical populations.
Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence
Cannabidiol (CBD) shows potential anxiolytic effects in pre-clinical and clinical research, but more research is needed to determine its efficacy in other anxiety disorders and its long-term efficacy.
Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.
Cannabidiol (CBD) did not improve treatment outcome in treatment refractory patients with anxiety disorders, as expected.
DOI